PM-8002

BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.

BioNTech's BNT327, a VEGF x PD-L1 bispecific antibody, demonstrates encouraging Phase II survival data in triple-negative breast cancer (TNBC).

BioNTech's BNT-327, a bispecific antibody targeting PD-L1 and VEGF, has demonstrated positive early results in patients with triple-negative breast cancer.

The FDA recently approved Imdelltra (tarlatamab-dlle) for extensive-stage SCLC, showing a 44% tumor shrinkage rate in relapsed or treatment-resistant cases.